Thus, considering the high seizure control rate in our patients (100%) compared with traditional treatments for corresponding epilepsy syndrome (e.g., ACTH and vigabatrin for IESS), we suggest that perampanel could be considered as the first-choice ASM for NR2F1-related epilepsy. The gene discussed is NR2F1; the disease is epilepsy.